Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 650x65px

Deals > All

Total search results: 10106 | Ordered by Date (descending)
1 2 3 ... 100 101 102  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Seekyo–Andrew Lloyd Associates: public relations, 202001 service existent by ALA 2020-01-20
Seekyo–EU (govt): credit, 202001 EIF Investment Initiation Loan €150k 2020-01-20
Seekyo–France (govt): credit, 202001 convertible bond €250k financing from French Tech Seed Fund managed by Bpifrance 2020-01-20
Seekyo–SEVERAL: investment, 202001 seed financing round €400k from investors from three business angel networks 2020-01-20
Piramal–Onex Corp: investment, 201901– acquisition Decision Resources by Clarivate Analytics from Piral Enterprises Ltd for $900m cash + $50m shares 2020-01-17
BioNTech–Covington & Burling: legal services, 202001 supply service legal counsel with regard to merger acquisition of Neon Therapeutics 2020-01-16
Neon Therapeutics–BioNTech: investment, 202001–acquisition merger $67m by BioNTech in all-stock transaction with 0.063 ADSs/share = $2.18/share 2020-01-16
Neon Therapeutics–Goodwin Procter: legal services, 202001 supply service legal counsel with regard to merger acquisition by BioNTech 2020-01-16
Neon Therapeutics–Ondra Partners: financial services, 202001 supply service excl financial advisor with regard to merger acquisition by BioNTech 2020-01-16
Scope Fluidics–Mindset Communication Support: public relations, 202001 service existent by Mindset CS 2020-01-16
Danaher–Sophia Genetics: genomic technologies, 202001– collab ww expansion IDT NGS enrichment products with Sophia Genetics DDM for clinical research 2020-01-15
Fibrocor Therapeutics–Galapagos: investment, 202001 equity investment by Galapagos as part of expanded collaboration 2020-01-15
Galapagos–Fibrocor Therapeutics: fibrosis drug, 202001– collab developm expansion excl license option for 4 addit small molecule inhibitor programmes 2020-01-15
Astellas–Adaptimmune: allogenic T-cell therapies, 202001– collab r+d CAR-T + TCR therapies with up to $897.5m for ADAP + up to $552.5m for Astellas 2020-01-14
Urania Therapeutics–France (govt): credit, 202001 repayable advances €850k from Bpifrance 2020-01-14
Urania Therapeutics–France (govt): grant, 202001 subsidies €850k from Bpifrance 2020-01-14
Andrew Alliance–Waters: investment, 202001 acquisition by existent investor Waters 2020-01-13
Daiichi Sankyo–ERS Genomics: CRISPR technology, 202001– license ww excl €na for internal r+d 2020-01-13
Domain Therapeutics–SEVERAL: credit, 202001 debt financing €6m fomr Bpifrance + BPALC + CIC + CEGEE 2020-01-13
Illumina–Roche: genomic cancer testing, 202001–201412 collab €na strategic alliance non-excl for NGS-based cancer testing for IVD + CDx 2020-01-13
Incyte–MorphoSys: tafasitamab, 202001– collab + ww excl license incl US co-commercialisation $750m upfront + $1.1b milestones 2020-01-13
MorphoSys–Incyte: investment, 202001 equity investment $150m in new ADSs at premium to share price as part of tafasitamab collab/license agreement 2020-01-13
Iovance–Cellectis: gene editing technology, 202001– collab + license ww excl for TILs in several cancer indications 2020-01-12
NBE Therapeutics–Boehringer: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor BIVF 2020-01-10
NBE Therapeutics–OTHER: investment, 202001 financing round Series C USD22m incl all existing private shareholders 2020-01-10
NBE Therapeutics–PPF Group: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor PPF Group 2020-01-10
NBE Therapeutics–SEVERAL: investment, 202001 financing round Series C USD22m led by existing investors BIVF + PPF Group wih all private investors 2020-01-10
Alderaan Biotechnology–Advent France Biotechnology: investment, 202001 financing round Series A totalling €18.5m incl existing investor AFB 2020-01-09
Alderaan Biotechnology–Medicxi: investment, 202001 financing round Series A totalling €18.5m incl new investor Medicxi 2020-01-09
Alderaan Biotechnology–SEVERAL: investment, 202001 financing round Series A €18.5m with Advent France Biotechnology + Medicxi 2020-01-09
Almirall–23andMe: therapeutic antibodies, 202001– license ww to bispecific MAb blocking all 3 isoforms of IL-36 2020-01-09
Almirall–WuXi PharmaTech: therapeutic antibodies, 202001– collab strategic r+d bispecific Abs for dermatology using WuXiBody antibody technology 2020-01-09
Sanofi–Nurix Therapeutics: protein degradation drugs, 202001– collab strategic ww $55m upfront + $2.5m milestones using DELigase platform 2020-01-09
Eyevensys–Bellevue: investment, 202001 financing round Series B totalling $30m incl new + co-investor Pureos Bioventures 2020-01-08
Eyevensys–Boehringer: investment, 202001 financing round Series B totalling $30m incl existing + lead investor Boehringer Ingelheim Venture Fund 2020-01-08
Eyevensys–CapDecisif: investment, 202001 financing round Series B totalling $30m incl existing + co-investor CapDecisif 2020-01-08
Eyevensys–France (govt): investment, 202001 financing round Series B totalling $30m incl existing + co-investors Bpifrance + Inserm Transfert 2020-01-08
Eyevensys–Pontifax: investment, 202001 financing round Series B totalling $30m incl existing + co-investor Pontifax 2020-01-08
Eyevensys–Quark Venture: investment, 202001 financing round Series B totalling $30m incl new + co-investor GHS Fund (Quark Venture + GF Securities) 2020-01-08
Eyevensys–RooneyPartners: public relations, 202001 service existent by RooneyPartners 2020-01-08
Eyevensys–SEVERAL: investment, 202001 financing round Series B $30m led by Boehringer Ingelheim Venture Fund 2020-01-08
NorthSea Therapeutics–BioGeneration Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor BGV 2020-01-08
NorthSea Therapeutics–Forbion: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Forbion 2020-01-08
NorthSea Therapeutics–New Science Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor NSV 2020-01-08
NorthSea Therapeutics–Novo Group: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Novo Seeds 2020-01-08
NorthSea Therapeutics–SEVERAL: investment, 202001 financing round Series B €36m led by new investor VenBio 2020-01-08
NorthSea Therapeutics–Sofinnova: investment, 202001 financing round Series B totalling €36m incl new + co-investor Sofinnova Investments 2020-01-08
NorthSea Therapeutics–VenBio: investment, 202001 financing round Series B totalling €36m incl new + lead investor VenBio Partners 2020-01-08
Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve 2020-01-08
Wellington Partners–MC Services: public relations, 202001 service existent by MC Services 2020-01-08
AstraZeneca–MiNA Therapeutics: saRNA therapeutics, 202001– collab €na research + license option for saRNA therapeutics for metabolic diaseses 2020-01-07
Boehringer–PhoreMost: drug discovery services, 202001– collab €na multi-project target discovery using Siteseeker platform 2020-01-07
MiNA Therapeutics–Trophic Communications: public relations, 202001 service existent by Trophic Communications 2020-01-07
PharmAkea–Galecto Biotech: investment, 202001– merger €na with new Galecto Inc in US with operational HQ in Copenhagen ANNOUNCED 2020-01-07
VectivBio–Cowen: investment, 202001 1st financing round totalling $35m incl Cowen Healthcare Investors 2020-01-07
VectivBio–France (govt): investment, 202001 1st financing round totalling $35m incl Bpifrance + Inserm Transfer Initiative 2020-01-07
VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings 2020-01-07
VectivBio–OrbiMed: investment, 202001 1st financing round totalling $35m incl OrbiMed 2020-01-07
VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. 2020-01-07
VectivBio–Tekla Capital: investment, 202001 1st financing round totalling $35m incl Tekla Healthcare Investors 2020-01-07
VectivBio–Versant Ventures: investment, 202001 1st financing round totalling $35m incl Versant Ventures 2020-01-07
VectivBio–WPP: public relations, 202001 service existent by Glover Park Group 2020-01-07
Velabs Therapeutics–Alytas Therapeutics: therapeutic antibodies, 202001– license excl for developm + commercialisation of Abs in field of senescence 2020-01-07
Integrated Biotherapeutics–Novo Group: investment, 202001 investment $3.9m in IBT Vaccines by Novo REPAIR Impact Fund 2020-01-06
Pharma Omnium–Novo Group: investment, 202001 investment €7m by Novo REPAIR Impact fund into Mutabilis 2020-01-06
Nabriva–Sam Brown: public relations, 201912 service existent by Sam Brown Inc 2019-12-20
Nabriva–SEVERAL: investment, 201912 registered direct offering $20m with 13.8m pairs ordinary share + warrant at $1.45/pair to institutional investors 2019-12-20
Savara–SEVERAL: investment, 201912– private placement $26.8m (with potential total proceeds of $75m) to institutional investors leb by Bain Capital LS 2019-12-20
CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance 2019-12-19
Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies 2019-12-19
Kinnate Biopharma–Nextech Invest: investment, 201912 financing round Series B totalling $74.5m incl new investor Nextech Invest Ltd 2019-12-19
Kinnate Biopharma–OrbiMed: investment, 201912 financing round Series B totalling $74.5m incl new investor OrbiMed 2019-12-19
Kinnate Biopharma–SEVERAL: investment, 201912 financing round Series B $74.5m from OrbiMed + Nextech Invest + Vida Ventures + Foresite + Eshelman 2019-12-19
Promega–Merck (DE): CRISPR technology, 201912– license to CRISPR IP io from Merck to Promega to develop CRISPR-edited cell lines 2019-12-19
BC Platforms–SEVERAL: investment, 201912 financing round Series C $15m led by Iqvia + incl Debiopharm Innovation Fund + Tesi 2019-12-18
Genomill Health–Avohoidon Tutkimussäätiö: investment, 201912 financing round incl co-investor Avohoidon Tutkimussäätiö 2019-12-18
Genomill Health–SEVERAL: investment, 201912 financing round led by Voima Ventures with Avohoidon Tutkimussäätiö 2019-12-18
Genomill Health–Voima Ventures: investment, 201912 financing round incl lead investor Voima Ventures 2019-12-18
KCR CRO–Veeva Systems: clinical research software, 201912– supply adoption of Veeva Vault CTMS by KCR 2019-12-18
Pathios Therapeutics–SEVERAL: investment, 201912 financing round Series A $8.8m with Canaan + MRCF managed by Brandon Capital 2019-12-18
Cellestia Biotech–SEVERAL: investment, 201912 financing round Series B CHF20m from FC Capital + PPF Group + Partners Investment + private investors 2019-12-17
Edinburgh Molecular Imaging–SEVERAL: investment, 201912 financing round £3.1m from new investor Caribou Property + existing investors 2019-12-17
Resistell–SEVERAL: investment, 201912 financing round Series A CHF3.5m 2019-12-17
Seer–aMoon: investment, 201912 financing round Series D totalling $55m incl lead investor aMoon Fund 2019-12-17
Seer–SEVERAL: investment, 201912 financing round Series D $55m led by aMoon + incl T Rowe Price + all existing plus other new investors 2019-12-17
Augustine Therapeutics–SEVERAL: investment, 201912 seed financing round €4.2m from V-Bio Ventures + PMV + Advent France + Gemma Vrisius + VIB 2019-12-16
Flagship Pioneering–WPP: public relations, 201912 service existent by Ogilvy 2019-12-16
Promethera–SEVERAL: investment, 201912 financing round Series D extension €7.5m bringing total round to €47.2m 2019-12-16
Aelis Farma–NewCap: public relations, 201912 service existent by NewCap 2019-12-13
Aelis Farma–SEVERAL: grant, 201912c research grants totalling €9m from various organisations incl US NIDA 2019-12-13
Aelis Farma–SEVERAL: investment, 201912 financing round €11m incl Region Nouvelle Aquitaine + Inserm Transfert Initiative + Bpifrance 2019-12-13
Start Codon–One Nucleus: business services, 201912– service support of start-ups participating in Start Codon accelerator programme by One Nucleus 2019-12-11
Abcalis–Germany (govt): grant, 201912 EXIST research transfer grant for founding from BMWi (plus ESF grant) 2019-12-10
Charles River–Bit Bio: drug discovery technology, 201912– collab strategic excl discovery + safety services partnership reprograming of human cells 2019-12-10
ImmunOs Therapeutics–SEVERAL: investment, 201912 financing round Series CHF15m co-led by Pfizer Ventures + BioMedPartners 2019-12-10
Inscripta–SEVERAL: investment, 201912 financing round Series D $125m led by Paladin Capital Group 2019-12-10
Schauenburg–JP Scientific: SPE technology, 201912– ww commercial license + supply to Markes from JP Scientific Ltd 2019-12-10
Algiax Pharmaceuticals–SEVERAL: investment, 201912 financing round €5.5m incl new investor Occident 2019-12-09
EMBL–Bruker: microscope, 201912 supply existent early customer EMBL for new Luxendo TruLive3D Imager 2019-12-09
Epidarex Capital–Zyme Communications: public relations, 201912 service existent by Zyme 2019-12-09
1 2 3 ... 100 101 102  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top